Stille AB (STIL) AI Stock Analysis

• Market Cap: kr1.55B
• Dividend Yield: N/A
• Average Volume (3M): 6.57K
• Price to Earnings (P/E): 38.4
• Beta (1Y): 0.28
• Revenue Growth: 13.36%
• EPS Growth: -20.56%
• Country: SE
• Employees: 162
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.49
• Shares Outstanding: 8,985,447
• 10 Day Avg. Volume: 9,615
• 30 Day Avg. Volume: 6,571
• PEG Ratio: 1.48
• Price to Book (P/B): 2.67
• Price to Sales (P/S): 3.28
• P/FCF Ratio: 31.55
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 66 Neutral
• Price Target: kr239.00 ▲(28.15% Upside)

Stille AB's strong financial performance is the primary driver of its stock score, supported by robust revenue growth and cash flow generation. However, technical indicators suggest bearish momentum, and the valuation appears high, limiting the overall score.

Positive Factors

Revenue Growth

Consistent revenue growth indicates strong market demand and effective sales strategies, which are crucial for long-term business expansion and sustainability.

Cash Flow Generation

Strong cash flow generation supports future investments and debt servicing, providing financial flexibility and stability for sustained growth.

Balance Sheet Health

A low debt-to-equity ratio indicates prudent financial management, reducing financial risk and enhancing the company's ability to withstand economic fluctuations.

Negative Factors

Net Profit Margin

Lower net profit margins compared to peers may indicate inefficiencies or higher costs, which could impact long-term profitability and competitiveness.

Earnings Growth

Negative EPS growth suggests challenges in translating revenue growth into higher earnings, potentially affecting investor confidence and future investment capacity.

Profitability

Moderate return on equity indicates potential underperformance in generating returns from shareholders' investments, which may limit attractiveness to investors.

Stille AB Business Overview & Revenue Model

Company Description

Stille AB develops, manufactures, and sells surgical instruments in Sweden and internationally. It offers artery forceps and ligature clamps; bone cutters and rongeurs; clamps, curettes, raspatories, elevators, forceps, and micro instruments; needle holders, and wire twisting and holding forceps; and osteotomes, chisels, retractors and skin hooks, scissors, and other products, as well as c-arm tables. The company also provides ERCP/abdominal fluoroscopy, neuro/spine, pain management, urology, and vascular surgeries. In addition, it provides instrument repair, maintenance, and inspection services. Further, the company's products are used in various open surgeries. It has a collaboration agreement with GE Healthcare and distribution agreement with Synovis Micro. The company sells through OEM manufacturers of C-frames, distributors, and direct sales. The company was founded in 1841 and is headquartered in Torshälla, Sweden. Stille AB is a subsidiary of Linc AB.

How the Company Makes Money

Stille AB generates revenue through the sale of its surgical instruments and medical devices to hospitals, clinics, and healthcare providers worldwide. The company's revenue model is primarily based on direct sales and distribution partnerships, which allow them to reach a broader market. Key revenue streams include the sale of surgical instruments, instrument sets, and disposable products. Stille also benefits from long-term contracts with healthcare institutions, ensuring a steady flow of income. Additionally, partnerships with other medical technology firms and participation in medical conferences and exhibitions help to enhance their market presence and drive sales.

Stille AB Financial Statement Overview

Summary

Strong overall fundamentals led by a debt-free balance sheet with sizable equity and assets. Profitability remains solid (healthy gross and EBIT margins), but margins and earnings have softened versus 2024, and free cash flow growth has turned negative despite positive OCF/FCF.

Income Statement

TTM (Trailing-Twelve-Months) results show solid profitability with ~52% gross margin and ~13% EBIT margin, though net margin is lower (~7%). Revenue has grown sharply versus the prior year period (RevenueGrowthRate ~2.01), but profitability has softened versus 2024 (EBIT and net income down; margins compressed from 2024 levels). Overall, the company looks structurally profitable, but the recent step-down in earnings quality keeps the score below top-tier.

Balance Sheet

The balance sheet is a clear strength: TTM (Trailing-Twelve-Months) shows zero debt and a sizable equity base (~693m) supporting a large asset base (~1.06bn). Leverage has improved meaningfully versus earlier years when debt-to-equity was materially higher, reducing financial risk. Return on equity is positive but modest in TTM (~5.8%) and below 2024, indicating the company is currently generating less profit per equity than it recently did.

Cash Flow

Cash generation is healthy in TTM (Trailing-Twelve-Months), with operating cash flow (~89m) and free cash flow (~74m) both positive, and free cash flow covering a large portion of net income (~0.83x). However, free cash flow growth is negative (about -4.95), and cash conversion remains less than one-for-one relative to earnings, suggesting some working-capital or reinvestment drag. Overall cash flow is good, but not consistently accelerating.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	552.55M	569.95M	294.89M	246.35M	187.09M	142.63M
Gross Profit	289.81M	295.64M	132.17M	111.57M	83.46M	57.43M
EBITDA	87.55M	118.97M	56.04M	44.78M	28.89M	15.68M
Net Income	40.41M	58.21M	26.65M	27.32M	16.10M	8.27M
Balance Sheet
Total Assets	1.06B	1.00B	804.89M	342.55M	308.85M	164.90M
Cash, Cash Equivalents and Short-Term Investments	138.51M	158.49M	241.45M	36.68M	27.80M	38.12M
Total Debt	0.00	63.09M	62.94M	70.77M	81.48M	24.10M
Total Liabilities	362.30M	301.70M	172.64M	152.74M	160.75M	53.85M
Stockholders Equity	692.75M	699.40M	632.25M	189.81M	148.10M	111.05M
Cash Flow
Free Cash Flow	74.13M	59.24M	24.37M	23.89M	-11.74M	-2.89M
Operating Cash Flow	89.06M	73.53M	37.28M	31.94M	7.28M	20.56M
Investing Cash Flow	-84.57M	-330.31M	-12.90M	-8.04M	-51.90M	-23.44M
Financing Cash Flow	40.00M	171.40M	178.99M	-18.54M	33.22M	-2.75M

Stille AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 186.50
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:STIL, the sentiment is Negative. The current price of 186.5 is above the 20-day moving average (MA) of 176.50, above the 50-day MA of 183.58, and below the 200-day MA of 203.98, indicating a bearish trend. The MACD of -4.89 indicates Positive momentum. The RSI at 43.79 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:STIL.

Stille AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STIL	66 Neutral	kr1.55B	38.36	―	―	13.36%	-20.56%
CRAD.B	66 Neutral	kr1.07B	45.72	6.93%	―	-5.80%	-65.99%
PAX	52 Neutral	kr1.08B	171.03	1.41%	―	21.71%	-80.37%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SEDANA	48 Neutral	kr997.34M	-24.54	-4.42%	―	13.48%	28.98%
OSSD	46 Neutral	kr1.02B	-22.47	―	―	38.43%	57.76%
SEZI	43 Neutral	kr786.08M	-5.77	-36.55%	―	62.24%	21.16%